FDA Approves Elaprase, Enzyme Replacement Therapy For Hunter's Syndrome
Filed in archive Drugs, Vaccines and Therapeutics , Drugs, Vaccines and Therapeutics by ruth on July 26, 2006
and potentially fatal disorder in children. Individuals afflicted with this disorder lack an enzyme called iduronate-2-sulfatase (I2S), and are unable to break down and recycle mucopolysaccharides, also known as glycosaminoglycans (GAG). When GAG accumulates in the body, symptoms of the disorder are manifested, which includes characteristic facial appearance, abnormal function of multiple organs, and in severe cases, early death.Elaprase is a purified form of I2S manufactured by recombinant DNA technology in a human cell line. It is given as weekly infusions, a therapy that is expected to be one of the world's most expensive medical treatments, at about $300,000 per patient per year.
More details from Shire's press release. More on Hunter disease from Hunterpatients.com.
Permalink: FDA Approves Elaprase, Enzyme Replacement Therapy For Hunter's Syndrome
Tags:
hereditary enzyme biotech therapy hunter hunter+syndrome elaprase+enzyme approves+elaprase
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/30241







